Neoadjuvant Archives - Page 3 of 4 - Agendia

Neoadjuvant therapy

Molecular subtyping by BluePrint improves prediction of treatment responses and survival outcomes in patients with discordant clinical and genomic classification

PUBLICATION: SABCS 2020 AUTHORS: Pat Whitworth, James V Pellicane, Jr., Read More

kevin2024-03-27T06:49:44-07:00December 29th, 2020|Evidence, NBRST, Neoadjuvant|

5-year outcomes in the NBRST trial: preoperative MammaPrint and BluePrint breast cancer subtype is associated with neoadjuvant treatment response and survival

PUBLICATION: SABCS 2020 AUTHORS: Pat Whitworth, James V Read More

kevin2024-03-07T10:56:07-08:00December 10th, 2020|Evidence, NBRST, Neoadjuvant|

I-SPY2: Pathologic Complete Response in Neoadjuvant Treatment of Stages 2 and 3 Breast Cancer

I-SPY2, JAMA Oncology, 2020 Authors: Yee et al.

Read More

Karen Guzdzial2024-03-28T11:26:31-07:00July 28th, 2020|Evidence, I-SPY2, Neoadjuvant|

ASCO 2020: Chemokine Signature
Gallery
ASCO 2020: Chemokine Signature

Evidence, NBRST, Neoadjuvant

ASCO 2020: Chemokine Signature

PUBLICATION: ASCO 20 AUTHORS: Hatem Soliman, Sangeetha Prabhakaran, Marilin Rosa, Read More

kevin2024-03-26T10:59:41-07:00May 29th, 2020|Evidence, NBRST, Neoadjuvant|

ASCO June 5 2019: Race and response to neoadjuvant chemotherapy
Gallery
ASCO June 5 2019: Race and response to neoadjuvant chemotherapy

Evidence, MammaPrint, NBRST, Neoadjuvant, Other, Racial Disparities

ASCO June 5 2019: Race and response to neoadjuvant chemotherapy

AUTHORS: Raquel Nunes, Femke de Snoo, Lisette Stork-Sloots, Tina Treece, Read More

kevin2024-03-25T08:51:00-07:00June 5th, 2019|Evidence, MammaPrint, NBRST, Neoadjuvant, Other, Racial Disparities|

NBRST: ER-positive basal-type breast cancers, respond like TNBC

NPJ Breast Cancer, April 2019 Author: Groenendijk et al.

Read More

Karen Guzdzial2024-04-16T11:49:27-07:00April 21st, 2019|Evidence, NBRST, Neoadjuvant|

Estrogen Receptor Variants in ER-Positive Basal-Type Breast Cancers Responding to Therapy Like ER-Negative Breast Cancers
Gallery
Estrogen Receptor Variants in ER-Positive Basal-Type Breast Cancers Responding to Therapy Like ER-Negative Breast Cancers

Evidence, NBRST, Neoadjuvant

Estrogen Receptor Variants in ER-Positive Basal-Type Breast Cancers Responding to Therapy Like ER-Negative Breast Cancers

PUBLICATION: npj Breast Cancer; volume 5, Article number: 15 (2019). Read More

kevin2024-03-25T08:54:30-07:00April 18th, 2019|Evidence, NBRST, Neoadjuvant|

BluePrint Luminal subtype predicts non-response to HER2-targeted therapies- I-SPY2
Gallery
BluePrint Luminal subtype predicts non-response to HER2-targeted therapies- I-SPY2

BluePrint, Evidence, HER2-positive, I-SPY2, Neoadjuvant, Other

BluePrint Luminal subtype predicts non-response to HER2-targeted therapies- I-SPY2

AACR, Poster 2612 AUTHORS: Pei Rong Evelyn Lee, Zelos Zhu, Read More

kevin2024-03-27T10:20:24-07:00April 18th, 2018|BluePrint, Evidence, HER2-positive, I-SPY2, Neoadjuvant, Other|

Pertuzumab/Trastuzumab/CT Versus Trastuzumab/CT Therapy for HER2+ Breast Cancer: Results from the Prospective Neoadjuvant Breast Registry Symphony Trial (NBRST)
Gallery
Pertuzumab/Trastuzumab/CT Versus Trastuzumab/CT Therapy for HER2+ Breast Cancer: Results from the Prospective Neoadjuvant Breast Registry Symphony Trial (NBRST)

BluePrint, Evidence, NBRST, Neoadjuvant

Pertuzumab/Trastuzumab/CT Versus Trastuzumab/CT Therapy for HER2+ Breast Cancer: Results from the Prospective Neoadjuvant Breast Registry Symphony Trial (NBRST)

PUBLICATION: Ann Surg Oncol. 2017 Sep;24(9):2539-2546. doi: 10.1245/s10434-017-5863-x. AUTHORS: Peter Read More

kevin2024-03-25T09:14:21-07:00April 26th, 2017|BluePrint, Evidence, NBRST, Neoadjuvant|

DNA Repair Deficiency Biomarkers and the 70-Gene Ultra-High Risk Signature as Predictors of Veliparib/Carboplatin Response in the I-SPY 2 Breast Cancer Trial
Gallery
DNA Repair Deficiency Biomarkers and the 70-Gene Ultra-High Risk Signature as Predictors of Veliparib/Carboplatin Response in the I-SPY 2 Breast Cancer Trial

Evidence, I-SPY2, Neoadjuvant

DNA Repair Deficiency Biomarkers and the 70-Gene Ultra-High Risk Signature as Predictors of Veliparib/Carboplatin Response in the I-SPY 2 Breast Cancer Trial

PUBLICATION: NPJ Breast Cancer. 2017 Aug 25;3:31. doi: 10.1038/s41523-017-0025-7. AUTHORS: Read More

kevin2024-02-22T12:01:50-08:00March 1st, 2017|Evidence, I-SPY2, Neoadjuvant|

Previous 234 Next

Agendia precision oncology

Quick Links

Our Tests
Resources
Landmark Trials
Order A Test
For Patients

Newsletter

Legal

Privacy Policy
Legal & Compliance
Terms & Conditions
Licenses & Accreditations
Code of Conduct

Contact

For the US, Puerto Rico, Canada
and South America
Agendia Inc. USA, 22 Morgan, Irvine, CA 92618
(888) 321-2732
customercare@agendia.com

For outside the Americas
Agendia NV, Radarweg 60, 1043 NT Amsterdam, The Netherlands
+31 (0)20 462 1510
customerservice@agendia.com

©2024 Agendia. All rights reserved. MammaPrint and Blueprint are registered trademarks of Agendia, Inc.